Stock COMBI COMBIGENE AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials CombiGene AB

Equities

COMBI

SE0016101935

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 09:54:36 2024-04-26 am EDT 		5-day change 1st Jan Change
3.77 SEK +0.27% Intraday chart for CombiGene AB -2.08% +40.15%
Mar. 13 CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries CI
Feb. 21 Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 35.52 79.45 71.23 157.3 225.7 180.9
Enterprise Value (EV) 1 30.6 47.65 63.07 108.4 88.99 49.11
P/E ratio -3.8 x -3.15 x -3.58 x -4.17 x 9.42 x -29.4 x
Yield - - - - - -
Capitalization / Revenue 11.8 x 21.6 x 4.75 x 14.5 x 2.48 x 6.3 x
EV / Revenue 10.2 x 12.9 x 4.21 x 10 x 0.98 x 1.71 x
EV / EBITDA - - -3,652,011 x -4,447,440 x 3,837,652 x -2,828,183 x
EV / FCF -4.96 x 10.7 x -5.89 x -3.73 x 6.84 x -4.04 x
FCF Yield -20.2% 9.31% -17% -26.8% 14.6% -24.7%
Price to Book 5.45 x 3.88 x 3.86 x 2.2 x 1.43 x 1.19 x
Nbr of stocks (in thousands) 826 2,580 3,253 11,464 19,801 19,801
Reference price 2 43.00 30.80 21.90 13.72 11.40 9.135
Announcement Date 4/13/18 4/25/19 6/8/20 5/4/21 4/27/22 4/26/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 3 3.686 14.99 10.83 91.15 28.73
EBITDA - - -17.27 -24.37 23.19 -17.36
EBIT 1 -8.958 -13.23 -18.44 -26.87 22.89 -17.66
Operating Margin -298.6% -358.87% -123.02% -248.12% 25.11% -61.47%
Earnings before Tax (EBT) 1 -8.958 -13.15 -17.93 -29.55 20.96 -6.157
Net income 1 -8.958 -13.15 -17.6 -29.38 20.96 -6.157
Net margin -298.6% -356.6% -117.46% -271.37% 23% -21.43%
EPS 2 -11.30 -9.778 -6.118 -3.287 1.210 -0.3109
Free Cash Flow 1 -6.168 4.437 -10.71 -29.05 13.01 -12.14
FCF margin -205.61% 120.35% -71.47% -268.34% 14.28% -42.27%
FCF Conversion (EBITDA) - - - - 56.12% -
FCF Conversion (Net income) - - - - 62.07% -
Dividend per Share - - - - - -
Announcement Date 4/13/18 4/25/19 6/8/20 5/4/21 4/27/22 4/26/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 4.92 31.8 8.17 48.9 137 132
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -6.17 4.44 -10.7 -29.1 13 -12.1
ROE (net income / shareholders' equity) -169% -97.5% -88% -64.4% 18.3% -3.97%
ROA (Net income/ Total Assets) -85.9% -38.2% -29.2% -27.3% 11.6% -6.81%
Assets 1 10.42 34.39 60.29 107.8 180 90.47
Book Value Per Share 2 7.880 7.930 5.680 6.230 7.990 7.680
Cash Flow per Share 2 5.950 12.30 4.660 4.270 6.910 6.660
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 4/13/18 4/25/19 6/8/20 5/4/21 4/27/22 4/26/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
COMBIGENE AB Stock CombiGene AB
+40.15% 6.81M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. COMBI Stock
  4. Financials CombiGene AB